By modulating expression of Ca2+ handling proteins, gene therapy targeting RyR2, SERCA2a and PLN is gaining fresh impetus recently, as one of the modalities to treat contractile dysfunction in DCM. This evidence concerns the gene CA2 and familial dilated cardiomyopathy.